A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine

Key facts

Sponsor

Pfizer

Principal Investigator

Pfizer CT.gov Call Center

Pfizer

Intervention

VLA15(biological)

Enrollment

1712 enrolled

Eligibility

7 years · All sexes

Timeline

2026 – 2026

Study locations (11)

• MaineHealth Pen Bay Hospital, Rockport, Maine, United States
• ActivMed Practices and Research, Methuen, Massachusetts, United States
• IMA Clinical Research Warren, Warren Township, New Jersey, United States
• Smith Allergy and Asthma Specialists, Cortland, New York, United States
• Smith Allergy & Asthma Specialists, Horseheads, New York, United States
• Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18), Pittsburgh, Pennsylvania, United States
• Guthrie Medical Group, P.C., Sayre, Pennsylvania, United States
• Robert Packer Hospital, Sayre, Pennsylvania, United States
• Northeast Clinical Trials Group, Scranton, Pennsylvania, United States
• Preferred Primary Care Physicians, Uniontown, Pennsylvania, United States
• Amherst Family Practice, P.C., Winchester, Virginia, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Lyme disease

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07561294
  A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)
  ModernaTX, Inc.
• RECRUITINGPHASE2NCT07562087
  A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure
  Tarsus Pharmaceuticals, Inc.
• RECRUITINGPHASE1, PHASE2NCT06785402
  Ceftriaxone for Post-Treatment Lyme Disease
  Hackensack Meridian Health
• ACTIVE NOT RECRUITINGPHASE3NCT07226882
  A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults
  Pfizer
• RECRUITINGPHASE4NCT06451913
  Effect of Saccharomyces Boulardii CNCM I-745 on Gut Microbiota in Patients Undergoing Antibiotic Therapy (in the Context of Erythema Migrans (Early Skin Form of Lyme Borreliosis))
  Biocodex
• RECRUITINGNANCT06915324
  Transcranial Direct Current Stimulation for Post Treatment Lyme Disease
  Columbia University
• RECRUITINGEARLY PHASE1NCT06611111
  Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease
  State University of New York - Upstate Medical University
• ACTIVE NOT RECRUITINGNCT06835075
  Clinicaly Manifested Reinfections with Borrelia Burgdorferi Sensu Lato
  University Medical Centre Ljubljana

See all trials for Lyme disease →